Account

Table 5 Review of the literature regarding oestrogen receptor concordance

From: Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature

	No of samples	Concordance (%)	IHC clone
Badoual, 2005 [25]	103	90.3	1D5, Immunotech
Burge, 2006 [26]	87	95	SF11, Biocare Medical
Hodi, 2007* [27]	338	98.8	1D5, Dako
Wood, 2007 [28]	100	95.8	ID11, Dako
Arnedos, 2009 [29]	336	98.2	SP1, Ventana
Tamaki, 2010 [30]	353	94.9	SF11, Ventana
Uy, 2010§ [31]	160	81.9	1D5, Dako
Lorgis, 2011° [32]	175	84	6F11, Novocastra
Ough, 2011 [33]	209	88	Not reported
Li, 2012# [34]	2450	92.8
Seferina, 2012° [35]	526	89.5	1D5, Dako
Dekker, 2013 [36]	122	99.1	1D5, Dako
Greer, 2013 [37]	205	89	6F11, Leica 1D5, Dako
Munch-Petersen, 2013 [38]	89	98	SP1, Dako
Motamedolshariati, 2014 [39]	30	96.7	Not reported
Chen, 2017 [40]	996	78.8	SP1, Ventana
Ensani, 2017 [41]	100	90	1D5, Biogenex
Kombak, 2017 [42]	284	93.3	6F11, Leica
Meattini, 2017° [43]	101	94.1	SF11, Ventana
You, 2017§ [44]	1219	97.1	SF11, Novocastra
Berghuis, 2019 [45]	684	95.5	Multiple
Jeong, 2020§ [46]	623	96.5	SP1, Ventana
Shanmugalingam, 2022 [47]	484	96.7	SP1, Ventana
Slostad, 2022 [48]	961	90.8	LDT

*McCarty’s h scoring system, #meta-analysis, ° positivity threshold: 10%, § Allred score, IHC, immunohistochemistry, LDT, laboratory-developed test.

Back to article page